Skip to main content

For Immediate Release June 01, 2016


Kevin Cservek:

GLEN BURNIE - University of Maryland Baltimore Washington Medical Center’s (UM BWMC) Tate Cancer Center is pleased to recognize the University of Maryland Marlene and Stewart Greenebaum Cancer Center for being awarded the National Cancer Institute’s (NCI) highest designation as a Comprehensive Cancer Center. The prestigious distinction recognizes the cancer center’s high caliber scientific leadership and robust programs in basic, clinical and population science research, placing it in the top tier of cancer centers nationwide. To reflect this new designation, the center is now named the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

The Tate Cancer Center is an affiliate of UMGCCC within the University of Maryland Cancer Network. Other affiliated centers within the network include UM St. Joseph Medical Center’s Cancer Institute and UM Upper Chesapeake Health’s Patricia D. and M. Scot Kaufman Cancer Center . Through the Network, these community cancer centers collaborate with UMGCCC on clinical research, and UM Cancer Network patients have access to the specialists, leading-edge technology and clinical trials at UMGCCC.

“We applaud the Greenebaum Comprehensive Cancer Center for achieving this highest standard of excellence in cancer research,” says Crystal Edwards, Executive Director of the Tate Cancer Center. “The Tate Cancer Center is committed to providing superior patient cancer care within our community. By aligning the quality, professionalism and convenience of our center with the innovation and scientific expertise of the Greenebaum Comprehensive Cancer Center, we are able to provide our patients with next-level cancer care.”

UMGCCC was granted NCI-designated Cancer Center status in 2008 and applied to become a Comprehensive Cancer Center last fall. NCI awarded the center the new designation after a rigorous review, which included a three-day site visit by 22 NCI reviewers in late February. The reviewers cited the cancer center’s “impressive progress” over the past five years and rated the center “outstanding.” The new designation goes into effect at the start of the cancer center’s next grant cycle August 1.

“We are extremely proud to have met the NCI’s exacting standards to be recognized as a Comprehensive Cancer Center and to be ranked in the very top echelon of cancer centers in the country,” says Kevin J. Cullen, MD, the Marlene and Stewart Greenebaum Distinguished Professor of Oncology at the University of Maryland School of Medicine and the cancer center’s director. “This designation will significantly enhance our ability to translate discoveries in the laboratory into better treatments for cancer patients in Maryland and beyond.”

Providing access to the benefits of academic medicine is what the UM Cancer Network is all about. “The Greenebaum Comprehensive Cancer Center is the heart of the UM Cancer Network,” says John A. Olson Jr., MD, PhD, professor of surgery and head of the Division of General and Oncologic Surgery at the UM School of Medicine, associate director of UMGCCC and clinical director of the UM Cancer Network. “This new designation is a testament to the quality of its physicians and researchers, and it impacts the care that the network can offer patients throughout Maryland.”

NCI Comprehensive Cancer Centers have comprehensive, well-integrated programs in population health, education and cancer prevention, as well as outstanding basic, clinical and translational research programs.

As a result of the new designation, the cancer center’s grant will increase 50 percent, to $1.5 million, and the center will be eligible for other funding from the NCI and other public and private sources. The Greenebaum Comprehensive Cancer Center is one of only 46 NCI-designated Comprehensive Cancer Centers in the United States.